Dr Reddy reports three FDA observations: what it means for Dr Reddy stock

Published on 10/15/2026 at 10:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dr Reddy disclosed three FDA observations at FTO-9 on October 14, 2026. Dr Reddy stock enters October 23 results with Q2 profit up 77.00 percent.

Regulatory filing and earnings date

The FTO-9 inspection ran from October 8 to October 9, 2026 and produced three observations.
September-quarter net profit rose 77.00 percent year over year to INR 5.04 billion.
Dr Reddy's next results are scheduled for October 23, 2026.

Dr Reddy, INE089A01023, Illustration mit AI erstellt.

Dr Reddy's Laboratories (ISIN INE089A01023) reported three USFDA observations at its FTO-9 manufacturing facility after an inspection from October 8 to October 9, 2026. According to the company's October 14 filing carried by StockTitan, Dr Reddy said it would address the observations within the stipulated timeline.

Three observations shape the filing

The disclosure concerns the company's FTO-9 site in Visakhapatnam, Andhra Pradesh, and a Form 483 issued by the US Food and Drug Administration. BusinessToday reported on October 15, 2026, that the filing did not quantify an immediate financial effect. For investors, the number of observations is the concrete regulatory marker, while the company's remediation statement sets the next point of attention.

What does the earnings comparison show?

The September quarter delivered a stronger reported profit base than the prior-year period. The Economic Times reported on October 11, 2026, that consolidated net profit rose 77.00 percent year over year to INR 5.04 billion, while consolidated net sales increased 7.00 percent to INR 37.97 billion. The comparison gives the regulatory filing a broader operating context, but it does not remove the need to monitor manufacturing execution.

Three dated steps to October

On July 22, 2026, Dr Reddy's Q1 revenue was reported at USD 853.00 million, down 5.60 percent year over year, according to Investing.com. From October 8 to October 9, the FTO-9 inspection produced three observations. The October 14 filing then placed those observations into the current regulatory timeline.

October 23 is the next date

Dr Reddy is scheduled to announce results for the quarter and six months ended September 30, 2026, on October 23, 2026. The earnings call is scheduled for 7:30 p.m. IST that day, according to ScanX. The results will show whether the September-quarter profit improvement continued into the next reporting period.

Stock remains tied to two dates

Dr Reddy's stock was last at INR 1,224.30 on India's NSE on October 15, 2026 at 1:50 p.m. IST. Its market capitalization was INR 1.0 trillion on that date, while the 52-week range was INR 1,101.00 to INR 1,414.90. The October 14 filing and the October 23 results date give investors two concrete milestones for assessing regulatory follow-through and operating performance.